NovaQuest Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

NovaQuest Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$5.43M	Sell	216,038 -382,947	-64%	-$10M	10.01%	2
2020 Q2	$14.6M	Hold	598,985	–	–	16.95%	2
2020 Q1	$8.87M	Sell	598,985 -959,441	-62%	-$19.8M	25.26%	2
2019 Q4	$25.3M	Hold	1,558,426	–	–	31.93%	2
2019 Q3	$20.3M	Hold	1,558,426	–	–	52.86%	1
2019 Q2	$20.2M	Hold	1,558,426	–	–	39.13%	2
2019 Q1	$24.6M	Hold	1,558,426	–	–	22.85%	2
2018 Q4	$31.4M	Hold	1,558,426	–	–	35.49%	2
2018 Q3	$38.7M	Hold	1,558,426	–	–	55.11%	1
2018 Q2	$42.8M	Hold	1,558,426	–	–	61.17%	1
2018 Q1	$48M	Sell	1,558,426 -1,538,224	-50%	-$49.5M	65.5%	1
2017 Q4	$111M	Buy	+3,096,650	New	+$88.9M	88.05%	1

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

NovaQuest Capital Management's RVNC Position: Q3 2020 in Review

NovaQuest Capital Management reduced its Revance Therapeutics, Inc. (RVNC) stake by 64% in Q3 2020, selling an estimated $10M and leaving 216,038 shares worth $5.43M. The position accounts for 10.01% of the portfolio, ranked #2.

NovaQuest Capital Management first reported a position in RVNC in Q4 2017 and has held it in 12 quarters since. The position peaked at $111M in Q4 2017. 153 funds tracked by Wall St. Rank hold RVNC as of Q3 2020.

NovaQuest Capital Management held 216,038 shares of Revance Therapeutics, Inc. worth $5.43M as of Q3 2020.
NovaQuest Capital Management sold 382,947 Revance Therapeutics, Inc. shares in Q3 2020, an estimated $10M.
Revance Therapeutics, Inc. made up 10.01% of NovaQuest Capital Management's portfolio in Q3 2020, its #2 holding.
NovaQuest Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2017 and has held it in 12 quarters since.
NovaQuest Capital Management's Revance Therapeutics, Inc. position peaked at $111M in Q4 2017.
153 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2020.

Based on NovaQuest Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.